A Randomized, Parallel, Double-Blind, Vehicle Controlled Study to Evaluate the Safety and Efficacy of Two Concentrations of Topical TMB-001 for the Treatment of Congenital Ichthyosis
Latest Information Update: 19 Mar 2024
At a glance
- Drugs Isotretinoin (Primary)
- Indications Congenital ichthyosiform erythroderma; X linked Ichthyosis
- Focus Therapeutic Use
- Acronyms CONTROL
- Sponsors Timber Pharmaceuticals; Trex Wind-down
Most Recent Events
- 15 Feb 2024 According to Timber Pharmaceuticals media release,Timber Pharmaceuticals has changed its name to Trex Wind-down
- 21 Aug 2023 According to a LEO Pharma media release, TMB-001 has received an breakthrough designation by the FDA, and is on track with an action date as early as mid-2025.
- 07 Jul 2023 Results of an analysis assessing characteristics of participants who responded to treatment with TMB-001 published in the Clinical and Experimental Dermatology